Roivant Sciences Ltd. (NASDAQ:ROIV) Short Interest Update

Roivant Sciences Ltd. (NASDAQ:ROIV) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 24,529,353 shares, a growth of 25.3% from the December 31st total of 19,579,958 shares. Approximately 4.0% of the shares of the stock are sold short. Based on an average trading volume of 6,681,612 shares, the days-to-cover ratio is presently 3.7 days. Based on an average trading volume of 6,681,612 shares, the days-to-cover ratio is presently 3.7 days. Approximately 4.0% of the shares of the stock are sold short.

Analyst Ratings Changes

ROIV has been the subject of a number of research reports. Citigroup upped their price objective on Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of Roivant Sciences in a research note on Thursday, January 22nd. Leerink Partners upped their price objective on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. HC Wainwright increased their target price on shares of Roivant Sciences from $23.00 to $26.00 and gave the company a “buy” rating in a report on Friday, December 12th. Finally, The Goldman Sachs Group lifted their price objective on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.19.

Insider Transactions at Roivant Sciences

In other news, major shareholder Vivek Ramaswamy sold 353,745 shares of Roivant Sciences stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $22.05, for a total transaction of $7,800,077.25. Following the completion of the sale, the insider owned 34,132,463 shares in the company, valued at approximately $752,620,809.15. This trade represents a 1.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Richard Pulik sold 406,731 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $22.43, for a total transaction of $9,122,976.33. Following the completion of the transaction, the chief financial officer owned 239,413 shares in the company, valued at approximately $5,370,033.59. This trade represents a 62.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 12,332,392 shares of company stock worth $266,393,645. 10.80% of the stock is owned by insiders.

Institutional Trading of Roivant Sciences

Large investors have recently bought and sold shares of the company. UBS Group AG raised its position in shares of Roivant Sciences by 570.0% in the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after acquiring an additional 15,645,836 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Roivant Sciences by 11,507.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock worth $150,535,000 after purchasing an additional 6,877,348 shares during the period. Perceptive Advisors LLC bought a new position in Roivant Sciences in the second quarter worth $37,546,000. Vanguard Group Inc. lifted its position in Roivant Sciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after buying an additional 3,254,113 shares during the period. Finally, Marshall Wace LLP boosted its holdings in shares of Roivant Sciences by 316.5% during the 3rd quarter. Marshall Wace LLP now owns 3,978,001 shares of the company’s stock valued at $60,187,000 after buying an additional 3,022,851 shares in the last quarter. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Stock Performance

ROIV stock traded down $0.46 on Wednesday, reaching $21.51. The company’s stock had a trading volume of 1,695,197 shares, compared to its average volume of 5,624,033. The firm has a market cap of $14.96 billion, a PE ratio of -38.43 and a beta of 1.22. The business has a fifty day simple moving average of $21.95 and a two-hundred day simple moving average of $17.62. Roivant Sciences has a 12-month low of $8.73 and a 12-month high of $23.91.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.